Elena Zamagni, MD, PhD, University of Bologna, Bologna, Italy, talks on the benefits of measurable residual disease (MRD) for patients with multiple myeloma, describing how sustained MRD negativity can be used to provide patients with more information on their response to treatment. This interview took place during the 18th International Myeloma Workshop (IMW 2021) congress.